US2020247774A1PendingUtilityA1
Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
Est. expiryNov 30, 2027(~1.4 yrs left)· nominal 20-yr term from priority
A61K 31/658A61P 25/28A61P 27/02A61P 19/00A61P 27/06A61P 19/06A61P 21/00A61P 29/00A61K 47/10A61P 1/02A61P 25/36C07D 311/74A61P 1/00A61P 31/22A61P 1/08C07D 311/80A61P 35/00A61P 1/14A61P 25/02A61P 31/10A61P 19/08A61P 37/00A61K 9/0014A61P 3/10A61P 39/06A61P 25/14A61P 21/04A61P 25/00A61P 21/02A61P 25/30A61P 17/08A61P 13/02C07F 9/65522A61P 37/02C07D 405/12A61P 17/00A61P 37/08A61P 43/00A61P 3/00A61P 31/18A61P 25/32A61P 25/04A61P 1/04A61P 3/04A61P 17/06A61P 17/02A61P 17/04A61P 25/18A61P 25/08A61P 37/06A61P 19/02A61K 9/7023A61K 31/352
73
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC. One embodiment described herein relates to the transdermal administration of a Δ9-THC prodrug for treating and preventing diseases and/or disorders.
Claims
exact text as granted — not AI-modified1 . A compound having the formula:
wherein R 1 is selected from an ester, a carbonate, a carbamate and a phosphate.
2 - 20 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.